HIV Drug Susceptibility and Treatment Response to Mega-Haart Regimen in Patients from the Frankfurt HIV Cohort

  title={HIV Drug Susceptibility and Treatment Response to Mega-Haart Regimen in Patients from the Frankfurt HIV Cohort},
  author={Veronica Miller and Alessandro Cozzi-Lepri and Kurt Hertogs and Peter Gute and Brendan Larder and Stuart Bloor and Stefan Klauke and Holger Felix Rabenau and Andrew Phillips and Schlomo Staszewski},
  journal={Antiviral Therapy},
  pages={49 - 55}
Objective To assess the relationship between viral susceptibility at baseline and virological response in human immunodeficiency virus (HIV)–infected patients treated with multi-drug salvage regimens after multiple previous treatment failures. Design Retrospective analysis of 50 patients from the Frankfurt HIV cohort who had received treatment with a minimum of six drugs, and for whom a sample for baseline viral phenotyping was available. Methods: Viral drug susceptibility was measured… 

Figures and Tables from this paper

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

Changes in surrogate markers suggest that treatment provided benefit in spite of virological failure and resistant virus, and patients with a shift to wild type virus responded better in the short term to treatment re-initiation.

Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy.

Data show that phenotypic susceptibility and absence of drug resistance mutations, particularly protease mutations, are significant predictors of virologic response and might provide useful clinical guidelines in selecting therapeutic options.

Evaluation of multiple drug therapy in human immunodeficiency virus-infected pediatric patients

Treatment of HIV-infected children with multiple drug therapy was well-tolerated in this cohort, and adherence affecting patients’ likelihood of success was a determining factor in treatment success or failure.

Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial

Clinicians did not observe clinical benefit or harm assessed by the primary outcome in this largest and longest trial exploring both ART interruption and intensification in advanced MDR HIV infection with poor retreatment options.

Clinical utility of HIV-1 genotyping and expert advice: the Havana trial

HIV-1 genotyping interpreted by a software package improves the virological outcome when it is added to the clinical information as a basis for decisions on changing antiretroviral therapy.

Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir

There was a good concordance among genotype and phenotype resistance testing, except for ABC, stavudine and didanosine, where phenotypic resistance testing added valuable information (fold change in the median inhibitory concentration).

Salvage antiretroviral therapy in HIV infection

It is important that new agents and new targets continue to be developed as an increasing number of patients in practice have exhausted all treatment options.

A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086.

Genetic analyses strongly suggest that virologic failure resulted from the reemergence of virus present before STI that encoded 3-drug class resistance on the same genome that encoded resistance mutations for 3 drug classes.

Update on HIV resistance and resistance testing

Both genotypic and phenotypic assays have been developed to assess HIV‐1 antiviral resistance and the more recently discovered mutation/drug resistance associations are discussed in terms of their implications for HIV resistance assays.

Management of HIV infection after triple class failure.

Strategies that might be effective options to obtain virologic success in patients with triple class failure, and treatment strategies for patients who do not have two active drugs to construct a new effective antiretroviral regimen afterVirologic failure are reviewed.



Virological response to protease inhibitor therapy in an HIV clinic cohort.

Starting protease inhibitors therapy with two other new antiretroviral drugs simultaneously with protease inhibitor therapy offers a better best chance of achieving sustained viral load < 500 copies/ml than starting fewer new drugs.

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy.

Failure of potent protease inhibitor therapy to suppress HIV RNA levels below detectable levels is common in clinical practice, and can often be explained by their suboptimal use.

Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting.

Baseline resistance to ritonavir or saquinvir or both was associated with a poor antiviral response, and the measurement of drug resistance may assist in optimizing antiretroviral therapy in the clinic.

The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan

Re-analysed studies confirmed the importance of both genotypic and phenotypic drug resistance as predictors of virological failure, whether these factors were analysed separately or adjusted for other baseline confounding factors.

Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.

Non-nucleoside reverse transcriptase inhibitors may represent a potent drug in salvage therapy regimens after failure of an indinavir or ritonavir regimen and Phenotypic resistance testing may provide a useful tool for selecting more effective salvage regimens.

Presence of Genotypic Resistance in Nucleoside Analogue-Treated HIV-1-Infected Patients with Undetectable Viral Load

Standard values of plasma viraemia for measuring the effectiveness of the treatment should be reconsidered when patients are on antiviral regimens of just two or three nucleoside analogues, as even in patients with undetectable viral loads by conventional methods, viral replication may continue and mutations develop.

Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV Infection

Drug interactions are likely to remain one of the major considerations when selecting a therapeutic regimen for patients with HIV, and the regimen of choice consists of 2 nucleoside analogues plus a protease inhibitor with high in vivo efficacy.

MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs

In the study of alternative or additional mechanisms of resistance operating during antiviral therapy, overexpression and amplification of the MRP4 gene correlated with ATP-dependent efflux of PMEA and azidothymidine monophosphate from cells and, thus, with resistance to these drugs.